Pharma channel feed

Mod­er­na soars in­to the ranks of the world's top phar­ma play­ers, now worth 3 Re­gen­erons

4 years ago
Bioregnum

Gilead joins the move­ment to man­date staff vac­ci­na­tions against Covid-19. And it looks like the rest of the in­dus­try is fol­low­ing

4 years ago

Ab­b­Vie hands back head­line drug in $63B Al­ler­gan buy­out to Mol­e­c­u­lar Part­ners af­ter FDA re­jec­tion. What's next?

4 years ago
Deals

Let­ter from FDA out­lin­ing de­fi­cien­cies for lead drug caus­es Ax­some stock to crater. Is a CRL on the way?

4 years ago
R&D
FDA+

Most Fa­vored Na­tions rule for drug pric­ing: Gone, but not for­got­ten

4 years ago

Sanofi wins ap­proval for Lu­mizyme suc­ces­sor, al­though up­take re­mains a mys­tery

4 years ago
FDA+

Fed­er­al cir­cuit up­holds Te­va-Glax­o­SmithK­line de­ci­sion, land­ing an­oth­er blow to 'skin­ny' la­bels

4 years ago

Courts to de­cide on whether drug­mak­ers have to sup­ply dis­count­ed drugs to un­lim­it­ed con­tract phar­ma­cies

4 years ago

Gilead warns of coun­ter­feit HIV pills cir­cu­lat­ing in some US phar­ma­cies

4 years ago

Mer­ck­'s Keytru­da takes home ad­ju­vant win in melanoma, es­ca­lat­ing ear­ly-line fight with Bris­tol My­ers

4 years ago
R&D

UK re-in­ves­ti­gates Pfiz­er's eye-pop­ping price goug­ing on an epilep­sy drug

4 years ago

Eli Lil­ly: As do­nanemab fil­ing ap­proach­es, ex­ecs 'even more con­fi­den­t' in da­ta pack­age

4 years ago
R&D

Bris­tol My­ers pulls lym­phoma in­di­ca­tion for Is­to­dax af­ter con­fir­ma­to­ry tri­al falls flat

4 years ago

How the bio­phar­ma in­dus­try is help­ing to pay for the bi­par­ti­san in­fra­struc­ture bill

4 years ago

Ab­b­Vie, rid­ing the Aduhelm af­ter­glow, hand­picks be­ta amy­loid drug for fur­ther R&D as it bails on tau

4 years ago
R&D

When is a drug in­tend­ed for a spe­cif­ic use? Not just when it's pro­mot­ed as such, FDA says in long-await­ed fi­nal rule

4 years ago
FDA+

FDA's on­col­o­gy head Rick Paz­dur de­fends the ac­cel­er­at­ed ap­proval path­way, claim­ing it is 'un­der at­tack'

4 years ago
FDA+

A tale of two vac­cines: As­traZeneca's shot still a block­buster, but Pfiz­er sales are on an­oth­er lev­el

4 years ago
Coronavirus

In­sulin biosim­i­lar wins first-ever in­ter­change­able des­ig­na­tion from FDA

4 years ago
FDA+

When a life-sav­ing vac­cine be­came a cash cow: Pfiz­er now projects $33.5B in Covid-19 vac­cine sales in 2021 alone

4 years ago
Coronavirus

Bris­tol My­er­s' Op­di­vo turns the boat around in Q2 as man­u­fac­tur­ing is­sues haunt CAR-T launch

4 years ago

Bio­gen push­es for broad CMS cov­er­age of Alzheimer's drug — while Eli Lil­ly looks to es­cape an NCD

4 years ago

Pan­el of neu­ro­science ex­perts lays out the com­pli­ca­tions with us­ing Bio­gen's new Alzheimer's drug

4 years ago
R&D
FDA+

J&J’s Rem­i­cade — the poster child for how to block biosim­i­lars — fi­nal­ly set­tles Pfiz­er suit

4 years ago
First page Previous page 239240241242243244245 Next page Last page
A service from the Financial Times